Concurrent Assessment of Skeletal Muscle Mass and Synthesis/Breakdown in Old Age

NCT ID: NCT04114383

Last Updated: 2020-03-25

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 37 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-06-07
• Study Completion Date: 2020-02-29

Brief Summary

This study involves minimally-invasive techniques to measure muscle mass, muscle protein breakdown and synthesis simultaneously in older age.

Detailed Description

Most people will have noticed that with age people become frail. This is principally due to wasting of skeletal muscle known as "sarcopenia". Crucially, sarcopenia is more than just a symptom of weakness and poor functional capacity; it exposes people to an increased risk of falls and fractures, impacting quality of life, independence, health status and ultimately lifespan. Muscles represent the largest organ in the body, making up over 50% of total body weight. Most people know that skeletal muscles are important for movement and to support the skeleton, but not everyone is aware of how important muscles are for whole-body health. For example, muscles represent a vast protein store containing amino acids (the building blocks of protein) which can be broken down in times of fasting, infection and disease in order to provide energy to help other vital organs. Because of the detrimental effects on health, and the associated health costs, sarcopenia is of grave concern. Therefore, there is a significant clinical need to pre-identify at-risk older individuals who have low muscle mass so that they can be offered an intervention (of diet, exercise or drug-based) before they suffer any of the potential problems outlined above. Current techniques for measuring whole-body muscle mass, including MRI and CT are time-consuming, expensive and in huge demand in hospital settings, meaning that muscle wasting conditions such as sarcopenia often go undiagnosed. In this project we propose a potential solution to this problem by developing a diagnostic of sarcopenia that requires only a single drink and subsequent urine collection. In addition, throughout this project we aim to explore the mechanisms underlying muscle wasting by assessing the muscle of those with low and 'normal' muscle mass.

Conditions

Sarcopenia; Muscle Atrophy

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

D3-Creatine

30mg D3-Creatine to measure muscle mass

Intervention Type: OTHER

Deuterium Oxide

D2O provided to measure muscle protein synthesis

Intervention Type: OTHER

D3-3-methylhistidine

D3-3-methylhistidine is provided to measure muscle protein breakdown

Intervention Type: OTHER

Other Intervention Names

D2O; Heavy water; D3-3MH

Eligibility Criteria

Inclusion Criteria

• Healthy volunteers of normal body mass index (BMI <35 kg/m2), aged 65-85 years

Exclusion Criteria

• A BMI > 35 kg/m2
• Active cardiovascular disease:

o angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event

• Cerebrovascular disease:

o previous stroke, aneurysm (large vessel or intracranial), epilepsy

• Respiratory disease including:

o pulmonary hypertension, COPD

• Metabolic disease:

o hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, type 1 or 2 diabetes

• Active inflammatory bowel or renal disease
• Malignancy
• Recent steroid treatment (within 6 months) or hormone replacement therapy
• Clotting dysfunction

• Minimum Eligible Age: 65 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Abbeyfield

UNKNOWN

Sponsor Role: collaborator

University of Nottingham

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Royal Derby Hospital Medical School

Derby, Derbyshire, United Kingdom

Countries

United Kingdom

Other Identifiers

Abbeyfield

Identifier Type: -

Identifier Source: org_study_id